Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
Eurasia—spanning Russia, Kazakhstan, Belarus, Armenia, and beyond—looks familiar on the surface: patents, regulatory approvals, and…

Pharmaceutical patent strategy is often treated like a spreadsheet exercise: list the patents, count the years, move on.
But the market doesn’t reward spreadsheets—it rewards timing, enforceability, and the ability to convert legal rights into predicta…

The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t just a scheduling detail. It’s a competitive weapon. The window between “launch” and “loss of exclusivity” can be measured in months, not years—and for commerc…

Before You Launch: The Freedom-to-Operate Checklist Pharma Teams Can’t Afford to Skip
In pharma, speed is a competitive advantage—until it isn’t.
A launch timeline that looks “on track” can collapse in a matter of weeks when a Freedom to Operate (FTO) …

Pharma procurement teams are sitting on a quiet risk radar—and most of them never turn it on.
Paragraph IV filings are one of those “if you know, you know” signals in the generic drug world. They’re not just legal paperwork. They’re a forward-looking i…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or counsel, you already know the headline numbers: patent terms, exclusivity windows, regulatory data protection…

Drug patent expiry dates aren’t just legal milestones—they’re commercial deadlines. And most teams treat them like a back-office calendar item instead of a revenue strategy. The result? Missed windows, late launches, and competitors who show up first w…

Sell the line before the patent breaks: a business development guide for solid-dose equipment suppliers targeting pre-LOE generic expansion
The most expensive mistake in pharma manufacturing isn’t buying the wrong machine. It’s arriving too late.
When …

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/